Exelixis Inc Goodwill
Exelixis Inc (EXEL) had Goodwill of $63.68 million as of 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:Goodwill · last filed 2026-08-05
- 2026-07-03: Goodwill $63.68M.
- 2026-04-03: Goodwill $63.68M.
- 2026-01-02: Goodwill $63.68M.
- 2025-10-03: Goodwill $63.68M.
| Period end | Goodwill |
|---|---|
| 2026-07-03 | $63.68M 10-Q · filed 2026-08-05 |
| 2026-04-03 | $63.68M 10-Q · filed 2026-05-05 |
| 2026-01-02 | $63.68M 10-Q · filed 2026-08-05 |
| 2025-10-03 | $63.68M 10-Q · filed 2025-11-04 |
| 2025-07-04 | $63.68M 10-Q · filed 2025-07-28 |
| 2025-04-04 | $63.68M 10-Q · filed 2025-05-13 |
| 2025-01-03 | $63.68M 10-K · filed 2026-02-10 |
| 2024-09-27 | $63.68M 10-Q · filed 2024-10-29 |
| 2024-06-28 | $63.68M 10-Q · filed 2024-08-06 |
| 2024-03-29 | $63.68M 10-Q · filed 2024-04-30 |
| 2023-12-29 | $63.68M 10-K · filed 2025-02-11 |
| 2023-09-29 | $63.68M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $63.68M 10-Q · filed 2023-08-01 |
| 2023-03-31 | $63.68M 10-Q · filed 2023-05-09 |
| 2022-12-30 | $63.68M 10-K · filed 2024-02-06 |
| 2022-09-30 | $63.68M 10-Q · filed 2022-11-01 |
| 2022-07-01 | $63.68M 10-Q · filed 2022-08-09 |
| 2022-04-01 | $63.68M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $63.68M 10-K · filed 2023-02-07 |
| 2021-10-01 | $63.68M 10-Q · filed 2021-11-02 |
| 2021-07-02 | $63.68M 10-Q · filed 2021-08-05 |
| 2021-04-02 | $63.68M 10-Q · filed 2021-05-06 |
| 2021-01-01 | $63.68M 10-K · filed 2022-02-18 |
| 2020-10-02 | $63.68M 10-Q · filed 2020-11-05 |
| 2020-07-03 | $63.68M 10-Q · filed 2020-08-06 |
| 2020-04-03 | $63.68M 10-Q · filed 2020-05-05 |
| 2020-01-03 | $63.68M 10-K · filed 2021-02-11 |
| 2019-09-27 | $63.68M 10-Q · filed 2019-10-30 |
| 2019-06-28 | $63.68M 10-Q · filed 2019-07-31 |
| 2019-03-29 | $63.68M 10-Q · filed 2019-05-01 |
| 2018-12-28 | $63.68M 10-K · filed 2020-02-25 |
| 2018-09-28 | $63.68M 10-Q · filed 2018-11-01 |
| 2018-06-29 | $63.68M 10-Q · filed 2018-08-01 |
| 2018-03-30 | $63.68M 10-Q · filed 2018-05-02 |
| 2017-12-29 | $63.68M 10-K · filed 2019-02-22 |
| 2017-09-30 | $63.68M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $63.68M 10-Q · filed 2017-08-02 |
| 2017-03-31 | $63.68M 10-Q · filed 2017-05-01 |
| 2016-12-31 | $63.68M 10-Q · filed 2017-11-01 |
| 2016-12-30 | $63.68M 10-K · filed 2018-02-26 |
| 2016-09-30 | $63.68M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $63.68M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $63.68M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $63.68M 10-K · filed 2017-02-27 |
| 2015-09-30 | $63.68M 10-Q · filed 2015-11-10 |
| 2015-06-30 | $63.68M 10-Q · filed 2015-08-11 |
| 2015-03-31 | $63.68M 10-Q · filed 2015-04-30 |
| 2014-12-31 | $63.68M 10-K · filed 2016-02-29 |
| 2014-09-30 | $63.68M 10-Q · filed 2014-11-04 |
| 2014-06-30 | $63.68M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $63.68M 10-Q · filed 2014-05-01 |
| 2013-12-31 | $63.68M 10-K · filed 2015-03-02 |
| 2013-09-30 | $63.68M 10-Q · filed 2013-10-30 |
| 2013-06-30 | $63.68M 10-Q · filed 2013-08-06 |
| 2013-03-31 | $63.68M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $63.68M 10-K · filed 2014-02-20 |
| 2012-09-30 | $63.68M 10-Q · filed 2012-11-07 |
| 2012-06-30 | $63.68M 10-Q · filed 2012-08-02 |
| 2012-03-31 | $63.68M 10-Q · filed 2012-05-03 |
| 2011-12-31 | $63.68M 10-K · filed 2013-02-21 |
| 2011-09-30 | $63.68M 10-Q · filed 2011-10-27 |
| 2011-06-30 | $63.68M 10-Q · filed 2011-08-04 |
| 2010-12-31 | $63.68M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |